Category Archives: Stem Cell Treatment

Brainstorm Cell Therapeutics (BCLI) Stock Gains Today on Potentially Positive Phase 2a Results

NEW YORK (TheStreet) -- Brainstorm Cell Therapeutics (BCLI) shares are up 9.13% to $5.02 as the biopharmaceutical company's stock gains momentum after the company announced that it will present positive results fromits phase 2a study of NurOwn when it releases the full set of data next weekat the American Academy of Neurology annual meeting.

The Israel-based developer of adult stem cell technologies for neurodegenerative diseases is developing NurOwn, a treatment being tested on patients with ALS or Lou Gehrig's disease, which is designed as a cell therapyin which bone marrow-derived mesenchymal stem cells are induced to secretfactors known to promote neuronal survival.

"We are thrilled to have the opportunity to share our results at this prestigious venue, and we look forward to discussing these findings with the medical community," said CEOTony Fiorino, MD, PhD. BCLI data by YCharts

Must Read: Warren Buffett's Top 25 Stocks for 2015

Link:
Brainstorm Cell Therapeutics (BCLI) Stock Gains Today on Potentially Positive Phase 2a Results

Mesoblast takes partnership with Celgene, shares rise 27pc

Mesoblast chief executive Silviu Itescu says new strategic partner Celgene has a "strong franchise and sales and marketing. Photo: Josh Robenstone

Mesoblast chief executive Silviu Itescu says a $58.5 million investment from pharmaceutical giant Celgene gives the company a strong potential route to market as the stem cell therapy developernears its first sales.

The American giant Celgene, which had revenue of $US7.7 billion ($10 billion) from treatments for cancers and inflammatory diseases like psoriasis, picked up 15.3 million shares at $3.82 a share. Investors welcomed the deal, pushing the volatile stock up 24 per cent to $3.99 on Monday.

The surge boosted the value of Mr Itescu's 22 per cent stake in the company by $53 million to $272 million.

Mesoblast shares have lost about 16 per cent in the past year, compared with a 10 per cent rise in the benchmark S&P/ASX 200 index.

The stock last traded at the placement price a month ago, but has traded as high as $5.75 in the past year. Mr Itescu said Mesoblast and Celgene began talks about six months ago. He described the deal as "a fair transaction".

"The right time is when you come to an arrangement with a strategic partner," he said. "Where the share price is at any given time is much less relevant to the value of the technology and the partnership."

As part of the deal, which gives Celgene a stake of about 4.5 per cent, the company will have first right of refusal over licensing deals for the commercialisation of Mesoblast's adult stem cell products in the treatment of certain diseases.

That is, if Mesoblast is approached by another company to licence itsdrug candidates for the prevention and treatment of acute graft versus host disease (GVHD), certain oncologic diseases, inflammatory bowel diseases, and organ transplant rejection, Celgene will have six months in which it can mull whether it would like to trump the deal.

Mr Itescu said Celgene has a "strong franchise and sales and marketing capability" in cancer and inflammatory diseases. He said Mesoblast's candidate for the treatment of graft versus host disease, a common complication of bone marrow transplants used to treat cancer, "fits perfectly well into their cancer and oncology franchise."

Read this article:
Mesoblast takes partnership with Celgene, shares rise 27pc

Study: Gene therapy superior to half-matched transplant for 'bubble boy disease'

Research first to compare alternative approaches to fully matched transplant for rare immune disorder

(WASHINGTON - April 13, 2015) - New research published online today in Blood, the Journal of the American Society of Hematology (ASH), reports that children with "bubble boy disease" who undergo gene therapy have fewer infections and hospitalizations than those receiving stem cells from a partially matched donor. The research is the first to compare outcomes among children with the rare immune disorder - also known as X-linked severe combined immunodeficiency (SCID-X1) - receiving the two therapeutic approaches.

Children with SCID-X1 are born with a genetic defect that prevents them from developing a normal immune system. Because they are prone to life-threatening infections, infants with SCID-X1 must be kept in a sterile, protective bubble and require extensive treatment for survival beyond infancy. Infants with SCID are most likely to survive if they receive a stem cell transplant from a fully matched donor - typically a sibling - a procedure that replaces an infant's diseased stem cells with healthy donor cells. Following a successful fully matched transplant, infants with SCID-X1 are able to produce their own immune cells for the first time.

In the absence of a fully matched stem cell donor, infants with SCID-X1 may receive a transplant from a partial, or "half-matched," donor - typically their mother or father. They may also undergo gene therapy, a much different approach. Gene therapy for SCID-X1 involves extracting an infant's own bone marrow, using a virus to replace faulty genetic material with a correct copy, and then giving "corrected" bone marrow back to the patient. Half-matched stem cell transplant and gene therapy represent secondary treatment approaches for infants with SCID-X1. Until recently, researchers had not yet compared outcomes among children treated with each respective approach.

"Over the last decade, gene therapy has emerged as a viable alternative to a partial matched stem cell transplant for infants with SCID-X1," said lead study author Fabien Touzot, MD, PhD, of Necker Children's Hospital in Paris. "To ensure that we are providing the best alternative therapy possible, we wanted to compare outcomes among infants treated with gene therapy and infants receiving partial matched transplants."

Dr. Touzot and colleagues studied the medical records of 27 children who received either partial-matched transplant (13) or gene therapy (14) for SCID-X1 at Necker Children's Hospital between 1999 and 2013. The children receiving half-matched transplants and the children receiving gene therapy had been followed for a median of six and 12 years, respectively.

The researchers compared immune, or T-cell, development among patients and also compared key clinical outcomes such as infections and hospitalization. Investigators observed that the 14 children in the gene therapy group developed healthy immune cells faster than the 13 children in the half-matched transplant group. In fact, in the first six months after therapy, T cell counts had reached normal values for age in more than three-fourths (78%) of the gene therapy patients, compared to roughly one-fourth (26%) of the transplant group. The more rapid growth of the immune system in gene therapy patients was also associated with faster resolution of some opportunistic infections (11 months in gene therapy group vs. 25.5 months in half-matched transplant group). These patients also had fewer infection-related hospitalizations (3 in gene therapy group vs. 15 in half-matched transplant group).

"Our analysis suggests that gene therapy can put these incredibly sick children on the road to defending themselves against infection faster than a half-matched transplant," Dr. Touzot said. "These results suggest that for patients without a fully matched stem cell donor, gene therapy is the next-best approach."

###

Blood, the most cited peer-reviewed publication in the field of hematology, is available weekly in print and online. Blood is the official journal of the American Society of Hematology (ASH), the world's largest professional society concerned with the causes and treatment of blood disorders.

Read the rest here:
Study: Gene therapy superior to half-matched transplant for 'bubble boy disease'

Awareness about Parkinson's disease on shaky ground

Parkinson's is an incurable progressive condition of the brain. It affects movement, speech and balance and causes incessant shivering of the face and limbs. Genetic and environmental factors are believed to contribute to the degeneration of brain cells that maintain bodily movement. There is no particular test to detect the disease, with only physical symptoms enabling doctors to make a diagnosis.

After 15 years of suffering and two failed stem cell transplantation surgeries, a 68-year-old businessman finally decided to undergo surgery on the eve of World Parkinson's Day at Jaslok Hospital. According to the doctors, the businessman, who is from Gujarat, had uncontrolled Parkinson's disease (PD) and was lured by the temptation of finding a 'cure' for the disease.

"He was lured by the temptation of finding a 'cure' for Parkinson's disease he underwent intracranial stem cell transplantation (a neurosurgical procedure) in Bangalore. As he did not obtain any benefit, he was given a 'top up' by the intravenous stem cell route. Obviously, none of these worked and his disease progressed," said Dr Paresh Doshi, Director, Neurosurgery Department at Jaslok Hospital.

As the disease progressed, Jain decided to go for deep brain stimulation (DBS) surgery, a standard surgical treatment for PD. "He had unbearable stiffness and discomfort and was taking large doses of medications. With the disease being in an advanced stage, DBS surgery was the only option," said Dr Doshi.

Since Jain had already undergone two operations, the team of neurosurgeons had a tough time executing the surgery. "Jain's case was tricky as the area we were interested in had already been operated on. Advanced technology and expertise helped us find our way into the brain and successfully accomplish the surgery," said Dr Doshi.

While Jain is now recuperating at the hospital, Dr Doshi said he is a classic example of poor awareness on PD. "The important message to convey is that stem cell treatment is a still at the laboratory stage. It can be tested on humans only after careful animal experimentation. So far, the efficacy of the stem cell therapy hasn't been proven and people shouldn't get misled," he said.

Neurologists say PD affects roughly one lakh people in India most of them over the age of 50, although it can sometimes affect younger adults. Awareness about the disease is a must in India, as the number of PD cases affecting those over the age of 60 are increasing sharply. "Parkinson's affects one in hundred individuals. While 55 crore Indians over 60 were afflicted in 2013, the number is estimated to triple to 160 crores by 2050. By then, over 22% of the Indian population will comprise of the elderly. It is therefore important to have more awareness on management of the disease," said Dr Doshi.

Dr Maria Barretto, CEO of Parkinson's Disease and Movement Disorder Society (PDMDS), which has twenty support groups in India including in Mumbai, Nasik and Baroda, agreed on poor general awareness about PD. "At PDMDS, we conduct various programs to spread awareness on the disease among both caregivers and the patients," she said.

Dr Charulata Sankhla, neurophysician at PD Hinduja Hospital who is also part of PDMDS, said that PD cases may be underreported due to lack of awareness. "Patients come to us very late because they don't recognise the symptoms. PD has to be diagnosed early, and it is very important to keep the patient active to ensure s/he has better mobility and a longer life."

Talking about surgery intervention, Dr Sankhla added that doctors would earlier wait for 5-6 years before taking a patient for surgery. However, surgery is being opted for in 3-4 years post the onset of PD. "Patients need to approach neurophysicians at the earliest so that it can be determined which stage of the disease the patient falls in. Treatment and surgery are recommended accordingly."

Continued here:
Awareness about Parkinson's disease on shaky ground

The New Botox: Stem Cell Therapy Cream Reviews- Wellington Anti Aging Centre Loxahatchee FL – Video


The New Botox: Stem Cell Therapy Cream Reviews- Wellington Anti Aging Centre Loxahatchee FL
The New Botox: Stem Cell Therapy Cream Reviews http://GoAgelessNow.com The New Botox: Stem Cell Therapy Cream Reviews Stem cell therapy is the use of stem cells to treat or prevent a disease.

By: Jamal Spikes

Link:
The New Botox: Stem Cell Therapy Cream Reviews- Wellington Anti Aging Centre Loxahatchee FL - Video

Degenerated Discs/Shoulder Arthritis 7 months after stem cell treatment by Harry Adelson, N.D. – Video


Degenerated Discs/Shoulder Arthritis 7 months after stem cell treatment by Harry Adelson, N.D.
Len describes his outcome seven months after fat-derrived stem cell treatment by Harry Adelson N.D. for his degenerated lumbar discs and arthritic shoulders http://www.docereclinics.com.

By: Harry Adelson, N.D.

Link:
Degenerated Discs/Shoulder Arthritis 7 months after stem cell treatment by Harry Adelson, N.D. - Video